APA (7th ed.) Citation

Tanguay, J., Catlow, C., Smith, C., Barber, J., Staffurth, J., Kumar, S., . . . Mason, M. (2016). High Risk of Neutropenia for Hormone-naive Prostate Cancer Patients Receiving STAMPEDE-style Upfront Docetaxel Chemotherapy in Usual Clinical Practice. Clinical Oncology, 28(9), 611. https://doi.org/10.1016/j.clon.2016.03.006

Chicago Style (17th ed.) Citation

Tanguay, J.S, C. Catlow, C. Smith, J. Barber, J. Staffurth, S. Kumar, N. Palaniappan, M. Button, and M.D Mason. "High Risk of Neutropenia for Hormone-naive Prostate Cancer Patients Receiving STAMPEDE-style Upfront Docetaxel Chemotherapy in Usual Clinical Practice." Clinical Oncology 28, no. 9 (2016): 611. https://doi.org/10.1016/j.clon.2016.03.006.

MLA (9th ed.) Citation

Tanguay, J.S, et al. "High Risk of Neutropenia for Hormone-naive Prostate Cancer Patients Receiving STAMPEDE-style Upfront Docetaxel Chemotherapy in Usual Clinical Practice." Clinical Oncology, vol. 28, no. 9, 2016, p. 611, https://doi.org/10.1016/j.clon.2016.03.006.